Intravitreal Bevacizumab Stabilizes Subfoveal CNV Secondary To AMD At 2 Years
Intravitreal bevacizumab improved visual acuity and macular thickness in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration, a study found.